Key takeaways for New Mexico
- • No GLP-1 is FDA-labeled for prediabetes — use is off-label.
- • Eligibility may still apply if BMI 30+ or 27+ with comorbidity (Wegovy/Zepbound).
- • Roughly 80-95% of prediabetic adults revert to normoglycemia in major trials.
- • Centennial Care coverage rules apply for Prediabetes patients in New Mexico — see Medicaid section below.
- • 13 GLP-1 telehealth providers available nationwide.
Why GLP-1 medications for Prediabetes
No GLP-1 drug carries an FDA prediabetes indication. However, in obese prediabetic adults, Wegovy and Zepbound are approved on the basis of BMI/comorbidity criteria, and both have been shown in trial post-hoc analyses to convert prediabetes back to normoglycemia in the majority of treated patients. Evidence grade: B (extrapolation from RCT subgroups). Lifestyle therapy and metformin remain first-line per ADA. GLP-1 use specifically for prediabetes is off-label and should be discussed with a physician.
New Mexico-specific context
New Mexico has telehealth access concentrated in Albuquerque, Las Cruces, Rio Rancho metros, with additional reach to Santa Fe and Roswell. University of New Mexico Health, Presbyterian Healthcare Services is the largest in-state academic medical center for endocrine + obesity-medicine specialty consults. The state health authority publishes prescribing + coverage updates at www.nmhealth.org.
New Mexicotelehealth & pricing rules
- • New Mexico permits audio-only and asynchronous telehealth visits for GLP-1 care.
- • New Mexico allows new-patient telehealth prescribing without a prior in-person visit.
- • Typical cash GLP-1 price in New Mexico: ~$245/mo (compounded options often lower, brand higher).
State telehealth statutes change — verify current rules with your provider before booking.